U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Criminal Investigations
  4. DOJ Press Releases involving FDA-OCI
  5. Pharmacist Indicted for Tampering with a Controlled Substance
  1. DOJ Press Releases involving FDA-OCI

Pharmacist Indicted for Tampering with a Controlled Substance

OCI Badge

Department of Justice
U.S. Attorney’s Office
District of Kansas

FOR IMMEDIATE RELEASE
Wednesday, February 16, 2022

KANSAS CITY, KAN. – A federal grand jury in Kansas City returned an indictment charging a pharmacist with one count of tampering with a consumer product, one count of possession of Tramadol by deception and subterfuge, one count of possession of Zolpidem by deception and subterfuge, and one count of possession of Oxycodone Hydrochloride by deception and subterfuge.

According to court documents, from July 2020 to October 2020, Benjamin Dandurand, 34, of Shawnee Mission is accused of allegedly using his fingerprint at a pharmacy in Lenexa to remove Oxycodone Hydrochloride from a safe. He allegedly removed the controlled substance from the bottle and replaced it with an alternate liquid substance before returning the bottle to the safe. Dandurand also allegedly took Tramadol, Oxycodone Hydrochloride, and Zolpidem from the pharmacy between September 2020 and October 2020.

The Food and Drug Administration and the Drug Enforcement Administration are investigating the case.

Special Assistant U.S. Attorney Michelle McFarlane is prosecuting the case.

An indictment is merely an allegation, and all defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.

###


 
Topic(s): 
Consumer Protection
Component(s): 
USAO - Kansas
 

Back to Top